Physician profile
Jeffrey B Rockoff
NPI 1902873839
$20,357.48
in general payments reported to CMS, 2019-2025
36 companies · $8,436 in 2025
The $8,436 reported for 2025 was more than what 84% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,796 · 2020: $1,133 · 2021: $1,553 · 2022: $1,745 · 2023: $2,317 · 2024: $2,376 · 2025: $8,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,924 · Consulting Fee: $5,544 · Travel and Lodging: $366 · Education: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,923.87 |
| Consulting Fee | $5,544.00 |
| Travel and Lodging | $365.62 |
| Education | $296.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $5,663.50 | 2019-2025 | |
| Genentech USA, INC. | $5,222.66 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $1,769.11 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,675.85 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $1,316.85 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Pfizer INC. | $710.89 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $544.58 | 2020-2025 | Glassia, Takhzyro, Cuvitru |
| Optinose US, INC. | $382.05 | 2019-2024 | |
| Grifols USA, LLC | $374.87 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Alk-Abello, INC | $324.95 | 2019-2025 | Grastek, Odactra, Ragwitek |
| Amgen INC. | $303.12 | 2021-2025 | Tezspire, Actimmune |
| Kaleo, INC. | $266.74 | 2019-2024 | Auvi-Q |
| Biocryst US Sales Co., LLC | $254.85 | 2021-2025 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $222.89 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.50 | 2019-2023 | Spiriva Respimat |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $188.71 | 2019-2022 | |
| Csl Behring | $171.05 | 2021-2025 | Hizentra, Andembry |
| Pharming Healthcare, INC. | $168.20 | 2019-2024 | Ruconest |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Octapharma USA, INC. | $67.44 | 2022-2025 | Cutaquig, Octagam Immune Globulin (Human) |
| Incyte Corporation | $51.81 | 2021-2023 | Opzelura |
| Covis Pharma Gmbh | $46.36 | 2021-2022 | |
| Horizon Therapeutics Plc | $38.10 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $32.29 | 2023 | Ryaltris |
| Phadia US INC. | $31.33 | 2021 | |
| Mylan Specialty L.P. | $29.31 | 2022-2024 | Yupelri |
| Uswm, LLC | $28.63 | 2021 | |
| Blueprint Medicines Corporation | $24.97 | 2025 | Ayvakit |
| Phathom Pharmaceuticals, INC. | $17.77 | 2024 | Voquezna |
| Biocryst Pharmaceuticals, INC. | $17.67 | 2020 | |
| Galderma Laboratories, L.P. | $17.66 | 2025 | Nemluvio |
| Bio Products Laboratory USA, INC. | $17.11 | 2023 | Gammaplex, Coagadex |
| Shire North American Group INC | $16.17 | 2019 | |
| Abbvie INC. | $15.87 | 2023 | Rinvoq |
| Organon LLC | $14.88 | 2025 | |
| Novartis Pharmaceuticals Corporation | $13.79 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Rockoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.